Skip to main content

Acorda Aktie - Fundamentalanalyse - Dividendenrendite KGV

Acorda Therapeutics (ISIN: US00484M1062, WKN: A0BK80) Kursdatum: 22.09.2017 Kurs: 23,450 USD
Beschreibung Daten
Symbol ACOR
Marktkapitalisierung 1.061.323.520,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.Russell 3000
Sektor Biotechnologie
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet
Letztes Bilanz Update 27.02.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 22.09.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
37,55 30,03 0,00% -2,56 49,48 -30,86 2,04 1,60

Firmenbeschreibung

 

 

 

 

 

(16) Quarterly Consolidated Financial Data (unaudited)

 

 

 

 

 

 

 

 

(In thousands, except per share amounts)

 

 

 

 

 

 

 

2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31

 

 

 

 

 

 

 

June 30

 

 

 

 

 

 

 

September 30

 

 

 

 

 

 

 

December 31

 

 

 

 

 

 

 

 

 

Total net revenues (1)

 

 

 

 

 

$99,851

 

 

 

 

 

$113,707

 

 

 

 

 

$148,199

 

 

 

 

 

$130,903

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

 

81,247

 

 

 

 

 

90,840

 

 

 

 

 

123,299

 

 

 

 

 

104,343

 

 

 

 

 

 

 

 

 

Net (loss) income—basic and diluted (2)

 

 

 

 

 

(3,085)

 

 

 

 

 

997

 

 

 

 

 

3,941

 

 

 

 

 

9,205

 

 

 

 

 

 

 

 

 

Net (loss) income per share—basic

 

 

 

 

 

$(0.07)

 

 

 

 

 

$0.02

 

 

 

 

 

$0.09

 

 

 

 

 

$0.22

 

 

 

 

 

 

 

 

 

Net (loss) income per share—diluted

 

 

 

 

 

(0.07)

 

 

 

 

 

0.02

 

 

 

 

 

0.09

 

 

 

 

 

0.21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31

 

 

 

 

 

 

 

June 30

 

 

 

 

 

 

 

September 30

 

 

 

 

 

 

 

December 31

 

 

 

 

 

 

 

 

 

Total net revenues

 

 

 

 

 

$80,518

 

 

 

 

 

$97,129

 

 

 

 

 

$105,961

 

 

 

 

 

$117,872

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

 

64,831

 

 

 

 

 

78,071

 

 

 

 

 

85,227

 

 

 

 

 

92,737

 

 

 

 

 

 

 

 

 

Net income—basic and diluted (3)

 

 

 

 

 

703

 

 

 

 

 

4,685

 

 

 

 

 

11,953

 

 

 

 

 

331

 

 

 

 

 

 

 

 

 

Net income per share—basic

 

 

 

 

 

$0.02

 

 

 

 

 

$0.11

 

 

 

 

 

$0.29

 

 

 

 

 

$0.01

 

 

 

 

 

 

 

 

 

Net income per share—diluted

 

 

 

 

 

0.02

 

 

 

 

 

0.11

 

 

 

 

 

0.28

 

 

 

 

 

0.01

 

 

 

 

 

 

 

 

 

 

 

 

(1)

 

 

 

In the third quarter of 2015, the Company recognized a one-time increase in net revenue of $22.2 million, representing previously deferred product sales for Zanaflex products due to the Company’s conversion from the deferred revenue recognition model (sell-through) to the traditional revenue recognition model (sell-in).

 

 

 

 

 

(2)

 

 

 

In the third quarter of 2015, the Company made a payment of $8.75 million to the former shareholders of Neuronex in exchange for certain modifications to the Company’s future contingent payment obligations pertaining to Plumiaz.  This payment was reflected as R&D expense.

 

 

 

 

 

(3)

 

 

 

In the fourth quarter of 2014 the Company realized a non-recurring impairment charge of $7.0 million to write-off the IPR&D related to the NP-1998 program.

 

 

 

 

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr.